摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-[(7R,9aS)-7-[4-amino-3-[4-[[4-(trifluoromethyl)pyridin-2-yl]carbamoyl]phenyl]imidazo[1,5-a]pyrazin-4-ium-1-yl]-4-oxo-3,6,7,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-2-methylpropanoic acid

中文名称
——
中文别名
——
英文名称
2-[(7R,9aS)-7-[4-amino-3-[4-[[4-(trifluoromethyl)pyridin-2-yl]carbamoyl]phenyl]imidazo[1,5-a]pyrazin-4-ium-1-yl]-4-oxo-3,6,7,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-2-methylpropanoic acid
英文别名
——
2-[(7R,9aS)-7-[4-amino-3-[4-[[4-(trifluoromethyl)pyridin-2-yl]carbamoyl]phenyl]imidazo[1,5-a]pyrazin-4-ium-1-yl]-4-oxo-3,6,7,8,9,9a-hexahydro-1H-pyrido[1,2-a]pyrazin-2-yl]-2-methylpropanoic acid化学式
CAS
——
化学式
C31H32F3N8O4+
mdl
——
分子量
637.6
InChiKey
UBHSRUKBULEUQC-IESUKNGTSA-O
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -0.8
  • 重原子数:
    46
  • 可旋转键数:
    6
  • 环数:
    6.0
  • sp3杂化的碳原子比例:
    0.35
  • 拓扑面积:
    154
  • 氢给体数:
    3
  • 氢受体数:
    12

文献信息

  • BTK INHIBITORS
    申请人:KIM RONALD M.
    公开号:US20140206681A1
    公开(公告)日:2014-07-24
    The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula I or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds in the treatment of Btk mediated disorders.
    本发明提供了根据式I提供的Bruton's酪氨酸激酶(Btk)抑制剂化合物,或其药学上可接受的盐,或包含这些化合物的药物组合物,并且用于治疗的使用。具体地,本发明涉及在治疗Btk介导的疾病中使用Btk抑制剂化合物。
  • Benzamide imidazopyrazine Btk inhibitors
    申请人:MERCK SHARP & DOHME CORP.
    公开号:US10087188B2
    公开(公告)日:2018-10-02
    The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula (I) in the treatment of Btk mediated disorders.
    本发明提供了根据式(I)的布鲁顿酪氨酸激酶(Btk)抑制剂化合物或其药学上可接受的盐,或包含这些化合物的药物组合物及其在治疗中的用途。特别是,本发明涉及式(I)的 Btk 抑制剂化合物在治疗 Btk 介导的疾病中的用途。
  • BENZAMIDE IMIDAZOPYRAZINE BTK INHIBITORS
    申请人:Merck Sharp & Dohme Corp.
    公开号:EP3240572A1
    公开(公告)日:2017-11-08
  • US9481682B2
    申请人:——
    公开号:US9481682B2
    公开(公告)日:2016-11-01
  • [EN] BENZAMIDE IMIDAZOPYRAZINE BTK INHIBITORS<br/>[FR] INHIBITEURS DE LA BTK DE TYPE BENZAMIDE IMIDAZOPYRAZINES
    申请人:MERCK SHARP & DOHME
    公开号:WO2016109223A1
    公开(公告)日:2016-07-07
    The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula (I) in the treatment of Btk mediated disorders.
查看更多

同类化合物

麦可弗汀A 六氢-2-甲基-2H-吡啶并[1,2-a]吡嗪-1,6-二酮 八氢吡啶并〔1,2-A〕吡嗪-6-酮 八氢吡啶并[1,2-a]吡嗪 八氢-吡啶并[1,2-A]吡嗪-4-酮盐酸盐 八氢-3-甲基-2H-吡啶并[1,2-a]吡嗪 八氢-2H-吡啶并[1,2-a]吡嗪-6-甲醇 7-甲氧基辛a氢-2H-吡啶并[1,2-a]吡嗪-2-胺 7-乙基八氢-2H-吡啶并[1,2-a]吡嗪-2-胺 6-甲基八氢-2H-吡啶并[1,2-a]吡嗪-2-胺 4H-吡唑[1,2-A]吡嗪-4-八氢酮 3-甲基八氢-2H-吡啶并[1,2-a]吡嗪-2-胺 2-苄基八氢-1H-吡啶并[1,2-a]吡嗪 2-硝基八氢-2H-吡啶并[1,2-a]吡嗪 2-乙基六氢-2H-吡啶并[1,2-a]吡嗪-1(6H)-酮 2-(9-甲基-3,9-二氮杂双环[3.3.1]壬-3-基)乙胺 2-(4-甲硫基唑-5-基)乙基丁酸酯 2,3,4,6,7,8,9,9alpha-八氢-1H-吡啶并[1,2-a]吡嗪-3-基甲醇 1,1'-联苯基,2-乙基-5-甲氧基- (R)-八氢吡啶并[1,2-A〕吡嗪二盐酸盐 (9aS)-八氢-4H-吡啶并[1,2-a]吡嗪-4-酮 (9aR)-八氢-2H-吡啶并[1,2-a]吡嗪 (9SS)-八氢-2-吡啶-吡嗪盐酸盐[1,2-A] (7r,9as)-八氢-2H-吡啶并[1,2-a]吡嗪-7-甲醇 (3S,6S)-3-苄基-1,4-二氮杂双环[4.4.0]癸烷-2,5-二酮 ((7S,9as)-八氢-1H-吡啶并[1,2-a]吡嗪-7-基)甲醇 ((6R,9as)-八氢-1H-吡啶并[1,2-a]吡嗪-6-基)甲醇 (S)-octahydro-2H-pyrido[1,2-a]pyrazine dihydrochloride (7R,9AS)-trans-(2,5-Difluoro-phenyl)-[7-(3-pyrrolidin-1-ylmethyl-phenoxymethyl)-octahydro-pyrido[1,2-a]pyrazin-2-yl]-methanone oxime (7RS,9ASR)-7-hydroxymethyl-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazine (6aα,10aα,11aα)-1,3,4,6,6a,7,8,9,10,10a,11,11a-Dodecahydro-2H-pyrazino-[1,2-b]isoquinoline-1,3-dione 17-β-cyanomarcfortine A 17-α-cyanomarcfortine A marcfortine A (trans)-benzyl 7-(8-chloroimidazo[1,5-a]pyrazin-3-yl)-4-oxohexahydro-1H-pyrido[1,2-a]pyrazine-2(6H)-carboxylate 3,5-dibromo-N-{(2S)-2-(4-fluorophenyl)-4-[3-(octahydro-2H-pyrido[1,2-a]pyrazin-2-yl)-azetidin-1-yl]butyl}-N-methylbenzamide acetate 2H-Pyrido[1,2-a]pyrazine, 2-[1-(3-fluorophenyl)ethyl]octahydro-3-methyl- 3-(4-octahydro-2H-pyrido[1,2-a]pyrazin-2-ylbutoxy)benzonitrile 1-[(7R,9aS)-2-BOC-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazin-7-ylmethyl]-1,3-dihydro-indol-2-one 2-<2-(3-indolyl)ethyl>-3-hydroxy-1-oxo-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido<1.2-a>pyrazine 2-<2-(3-indolyl)ethyl>-1-hydroxy-3-oxo-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido<1.2-a>pyrazine (1R,3R)-11,14-Dihydroxy-16-(hydroxymethyl)-13-methoxy-12,20-dimethyl-5-oxa-8,17,20-triazahexacyclo[15.3.1.03,19.04,8.09,18.010,15]henicosa-10(15),11,13-triene-21-carbonitrile trans-perhydrodiazaphenanthrene cis-perhydrodiazaphenanthrene tert-butyl (1aR,4S,6aR,7aR)-4-{[(1S,2S)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]carbamoyl}octahydro-5H-cyclopropa[4,5]pyrrolo[1,2-a]pyrazine-5-carboxylate 2-benzyl-hexahydro-6H-pyrido[1,2-a]pyrazine-1,4-dione (7R,9aS)-2-BOC-7-(4-fluorophenoxy)methyl-2,3,4,6,7,8,9,9a-octahydro-1H-pyrido[1,2-a]pyrazine trans-7-(3-piperidin-1-ylpropoxymethyl)-octahydro-pyrido[1,2-a]pyrazine-2-carboxylic acid tert-butyl ester 2-(2-Fluoro-benzenesulfonyl)-octahydro-pyrido[1,2-a]pyrazin-6-one (3S,6R)-3-Benzyl-1,4-diazabicyclo<4.4.0>decane-2,5-dione